Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott’s Humira demonstrates long-term efficacy in studies

Abbott’s Humira demonstrates long-term efficacy in studies

25th November 2010

Abbott has published data from two open-label studies of its Crohn's disease treatment Humira, demonstrating the drug's efficacy over a long-term period.

The adalimumab therapy was evaluated in the recent Adhere and Classic II clinical studies, which collectively involved almost 400 patients and assessed Humira's benefits over the course of at least three years of open-label treatment.

It was found that the majority of Humira users whose conditions went into remission after the first year remained in remission after two additional years.

This data will now be added to the treatment's label in EU countries, including the UK.

Dr James Lindsay, consultant gastroenterologist at Barts and the London NHS Trust, said it is important that Crohn's sufferers have access to a therapy that keeps the condition under control.

He added: "This three-year efficacy data offers increased confidence to clinicians who may be prescribing adalimumab for their Crohn's patients."

This comes after Abbott published additional Humira data earlier this month, demonstrating its effects among rheumatoid arthritis patients.ADNFCR-8000103-ID-800255898-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.